Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q1 2026: Viking Therapeutics 0, Structure Therapeutics 0.
Viking Therapeutics vs Structure Therapeutics Net Worth and Market Cap
Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are peers in GLP-1. Viking Therapeutics reported revenue of $0 as of Q1 2026, compared with $0 for Structure Therapeutics.
Key differences
- Viking Therapeutics's KPIs on Sterling include Cash + Short-Term Investments (Quarterly) and Viking Oral VK2735 Phase 3 Timing.
- Structure Therapeutics's KPIs on Sterling include ACCOMPLISH Phase 3 Design and Aleniglipron (GSBR-1290): Trial Pipeline and Phase 2 Readouts.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Viking Therapeutics, Structure Therapeutics.| Metric | Viking Therapeutics | Structure Therapeutics |
|---|---|---|
| Market Cap | - | - |
| Revenue | $0 | $0 |
| Cost of Revenue | $0 | $1.00M |
| Gross Profit | $0 | $-1.00M |
| Operating Income | $-164.00M | $-90.00M |
| Net Income | $-158.00M | $-76.00M |
| R&D Expense | $150.00M | $67.00M |
| Earnings Per Share | -$1.37 | -$1.05 |
| Gross Margin | - | - |
| Operating Margin | - | - |
| Net Profit Margin | - | - |
| Free Cash Flow | $-114.00M | $14.00M |
| Cumulative Free Cash Flow | $-747.00M | $-469.00M |
| Operating Cash Flow | $-114.00M | $15.00M |
| Cash & Equivalents | $118.00M | $316.00M |